Immuno-Oncology

The European Commission has approved pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy.

Jonathan Riess, MD, assistant professor of medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses the long-term benefit with immunotherapy for patients with lung cancer.

The FDA released a statement today providing specific data from 2 phase III trials of pembrolizumab in multiple myeloma that the agency placed clinical holds on in July.

David R. Gandara, MD, discusses the latest immunotherapy developments in lung cancer and the next steps toward optimizing the benefit of these agents.

Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer and the potential for combinations with this agent.

Adil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the current status of immunotherapy in melanoma.

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses efficacy findings of a study investigating the combination of pembrolizumab (Keytruda) and rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.

The combination of frontline atezolizumab and bevacizumab demonstrated superior efficacy compared with sunitinib or atezolizumab monotherapy in patients with advanced renal cell carcinoma.

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).

Peter Black, MD, discusses the latest on durvalumab and other ongoing developments in the field of bladder cancer.

Robert Andtbacka, MD, discusses the long-term results for T-VEC in melanoma and the remaining challenges with the oncolytic immunotherapy.

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of modern immunotherapies in the landscape of mantle cell lymphoma (MCL).

Charles Drake, MD, PhD, shares his insight on the promise and challenges with immunomodulatory drugs, and immune-activating agents in prostate cancer.

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the science behind the results of a study investigating sipuleucel-T (Provenge) for patients with castration-resistant prostate cancer (CRPC).

Lyudmila A. Bazhenova, MD, discusses the non-driver NSCLC population, the treatment strategies available for them, and challenges physicians continue to face with this subgroup of patients.

Moshe Ornstein, MD, staff, Cleveland Clinic, discusses the challenges surrounding immunotherapy for patients with renal cell carcinoma.

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses approaches of immunotherapy for patients with prostate cancer.